Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for BMF-650 (GLP-1 RA) in Obese, otherwise healthy volunteers. The expected timing is based on the latest available company guidance and may change.
GLP-131 trial. 10/27/25- First patient dosed. 11/4/25- IND accepted. 11/5/25- Enrollment ongoing. 28-day weight loss data in H1 2026. 01/12/26:- SAD/MAD cohorts and final 28-day weight-loss data expected Q2 2026. 03/24/26:- GLP-131 Phase I enrollment ongoing; initial 28-day weight reduction data expected in Q2 2026. 05/11/26:- GLP-131 Ph1 obesity trial ongoing and on track; initial 28-day weight-loss data expected Q2 2026. 06/05/26:- GLP-131 added rapid titration MAD cohort; initial 28-day weight-loss data now expected Q3 2026. 08/05/26:- GLP-131 Ph1 remains on track; 28-day weight-loss data expected Q3 2026.
Verification
Confirm timing and program details against the company announcement or filing.